Company Overview
Target RWE cultivates a distinctly collaborative enterprise unifying unique real world data and advanced analytics in a cohesive ecosystem to improve lives
Designed to Meet Your Real-World Evidence Needs
Target RWE is redefining and revolutionizing the generation and delivery of real-world evidence. With high-quality and comprehensive fit-for-use datasets captured across a broad range of chronic illnesses, Target RWE is well-positioned to support pharmaceutical, industry, life sciences, and healthcare partners with their RWE initiatives and programs.
We design custom datasets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives. Our regulatory-grade data has been leveraged to support new drug development and label expansion opportunities, address regulatory demands, assess decision-making processes for research and development strategies such as sales, marketing, and pricing, as well as fulfill post-marketing drug safety requirements/commitments in the United States and Europe.
Company Values
Innovation
Real-world data are complex, and accurate learning requires a critical mass of epidemiologic, statistical, and subject matter expertise. We approach every task with an open mind to explore inventive methodologies, strategic partnerships, and new ways of thinking to generate the best data and evidence. We promote forward-thinking, advanced research and nurture the creativity of our scientific, medical, and technical teams. We strive to produce accurate, timely, and bias-free answers by employing the most appropriate epidemiologic designs and statistical analyses.
Ethics & Transparency
We believe transparency is a leading factor in building trustworthy relationships with clients, stakeholders, and employees. Our company is challenged each day to answer and address difficult questions in the healthcare community, which requires increased levels of transparency and clear channels of communication that are essential to developing trust. Our scientific work focuses on strong ethical conduct and practices to address important research questions in the healthcare community.
Inclusion
We believe in the value and importance of all people. This value underpins our research ethics and commitment to studying underrepresented populations, as well as extends to our relationships with employees, collaborators, and clients. We are committed to fostering a culture of inclusion and to maintaining a workplace characterized by mutual respect, where all people feel authentically like themselves, feel included, listened to, and are fairly treated. We seek to understand each person's strengths and motivators to create an optimal work experience and environment.
Evolution
As a company, we push ourselves to constantly assess how we can continue to grow and evolve. We encourage a culture of discovering new approaches, the latest technologies, and areas of opportunity in the market to improve results and provide the most value for our clients. We aim to build adaptive health evidence solutions, and we are driven to make an impact with our real-world data and scientific intelligence solutions.
Who is Target RWE?
Company History
Target RWE was created in 2015 as an outcome of the success of HCV-TARGET, a case study of the Target RWE Model for hepatitis C. HCV-TARGET was a partnership between academia, the FDA and industry established in 2011 by Michael W. Fried, MD, FAASLD and David R. Nelson, MD. To date, the study has enrolled over 16,000+ patients across 60 sites in North America and Europe.
The evidence from HCV-TARGET has been utilized by regulators to monitor post-marketing drug safety, and by sponsors to support label expansion and mitigate phase IV commitments. In late 2018, Dr. Fried and members of the HCV-TARGET team were awarded the Civilian Honor Award for Regulatory Science Excellence by the FDA “for outstanding public-private partnership leveraging real-world evidence.”
The HCV-TARGET case study has helped inform national and international treatment guidelines and was used in payer dossiers. As a result, numerous high impact scientific presentations and manuscripts were published - generating 9 publications and 30+ abstract presentations. The proven success of the HCV-TARGET collaborative model and platform was the basis of Target RWE's foundation in 2015 and its expansion into various disease indications.
